Nuwellis, Inc. 8K

Nuwellis, Inc. reported improved second quarter 2026 financial results, strengthened its balance sheet with recent equity financings that extend its cash runway, advanced Aquadex label expansion efforts, and appointed Mike McCormick as its new President and CEO.

On August 13, 2026, Nuwellis, Inc. announced its financial results for the quarter and six months ended June 30, 2026, highlighting 14% year‑over‑year quarterly net sales growth to $2.0 million, a substantial gross margin improvement to 76% from 56%, and increased console sales that expand the installed base for recurring circuit revenue. The company reported a quarterly net loss of approximately $4.8 million, including $1.7 million of non‑cash warrant valuation expense, and detailed operating expenses tied to commercial expansion and product development. Nuwellis also disclosed that it raised $6.0 million in gross proceeds via a June 2026 registered direct offering and subsequently raised an additional approximately $6.7 million in July 2026 through a financing and warrant exercises, which together extend its cash runway through the second quarter of 2027 and simplify its capitalization structure. Operationally, the company advanced a proposed Aquadex label expansion to patients weighing 5 kilograms or more following a positive FDA pre‑submission meeting and underscored growth in its pediatrics and critical care customer segments. Additionally, Nuwellis announced the appointment of Mike McCormick as President and Chief Executive Officer, effective June 30, 2026, and scheduled a same‑day conference call to discuss these results and strategic priorities.

Filing Facts

CIK

1506492

Ticker

-

Form

8K

Source Type

sec

Accession

0001140361-26-032838

Alert Tier

7